The research plan involves studying three distinct mutations in the fusion gene P210 BCR/ABL, the molecular hallmark of the Philadelphia Chromosome (Ph') of Chronic Myelogenous Leukemia (CML). These mutations involve areas of BCR/ABL recently shown to have potentially important roles in how it causes transformation in several in vitro systems. The three mutations include: (1) deletion of the SH2 domain, a conserved regulatory region in c-Abl and many other proteins, important in signal transduction between proteins phosphorylated on tyrosine and mediators of proliferation and differentiation; (2) a point mutant in a region of BCR (Y177F) shown to be an important link between Ras and BCR/ABL in cellular transformation; (3) deletion of a region in the carboxy-terminus of c-Abl that has recently been shown to mediate the interaction of Abl with the F-actin cytoskeleton. Much remains to be learned about whether these regions are important in transformation of hematopoietic cells in tissue culture and in vivo. The basic res arch design to accomplish these goals consists of two phases, the first involves studying these mutations in tissue culture, and the second will be to use the insight gained in vitro to establish in vivo relevance by studying their effects in murine bone marrow transplant experiments. In the first part, these mutant constructs will be introduced into the murine hematopoietic factor-dependent cell liens Ba/F3 (lymphoid), and FDCP-1 (myeloid) by retroviral gene transfer and electroporation, respectively. Outcome will be assessed by how these P210BCR/ABL mutants compare in their ability to transform these cells to growth factor independence compared to wild type P210. In the second phase these mutants will be introduced into murine bone marrow cells by a Rat-1 fibroblast retroviral packaging cell lin. After infection, the marrow cells will be used to reconstitute syngeneic lethally irradiated recipients, and the incidence and leukemic phenotype which results will be compared to parallel P210 controls. These studies will provide important insight into the pathogenesis of BCR/ABL- related malignancies, and perhaps someday benefit patients suffering from these diseases.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08HL003310-05
Application #
6030360
Study Section
Special Emphasis Panel (ZHL1-CSR-Y (F1))
Project Start
1995-07-01
Project End
2000-06-30
Budget Start
1999-07-01
Budget End
2000-06-30
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Dallas
State
TX
Country
United States
Zip Code
75390
Ilaria Jr, Robert L (2004) Animal models of chronic myelogenous leukemia. Hematol Oncol Clin North Am 18:525-43, vii
Ye, Dan; Maitra, Anirban; Timmons, Charles F et al. (2003) The epidermal growth factor receptor HER2 is not a major therapeutic target in Ewing sarcoma. J Pediatr Hematol Oncol 25:459-66
Eliazer, Susan; Spencer, Jeffrey; Ye, Dan et al. (2003) Alteration of mesodermal cell differentiation by EWS/FLI-1, the oncogene implicated in Ewing's sarcoma. Mol Cell Biol 23:482-92
Roumiantsev, S; de Aos, I E; Varticovski, L et al. (2001) The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood 97:4-13
Spencer, J A; Eliazer, S; Ilaria Jr, R L et al. (2000) Regulation of microtubule dynamics and myogenic differentiation by MURF, a striated muscle RING-finger protein. J Cell Biol 150:771-84
Silvany, R E; Eliazer, S; Wolff, N C et al. (2000) Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation. Oncogene 19:4523-30
Li, S; Ilaria Jr, R L; Million, R P et al. (1999) The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 189:1399-412
Ilaria Jr, R L; Hawley, R G; Van Etten, R A (1999) Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood 93:4154-66
Ilaria Jr, R L; Van Etten, R A (1996) P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 271:31704-10